If the past is truly prologue, it seems reasonable to predict that the first part of the new Millennium will bring significant advances in our understanding of Multiple Sclerosis (MS) . At the close of the nineteenth century, the most important information available was Charcot's elegant clinical and histopathologic descriptions, work that has stood the test of time. As the twenty-first century begins, the available facts represent a veritable information explosion, much of which has developed in the past 25 years.
A few signal examples include: Electron microscopy of the MS lesion has made it clear the limited remyelination occurs in many individuals. The addition of sophisticated immunopathologic studies suggests the possibility that more than one pattern of disease development exists. As an extension of direct studies of tissue, magnetic resonance imaging and spectroscopy, and their emerging variations, permit incredibly sensitive detection and quantification of affected areas in vivo{rm}. Further, the promise of functional imaging in understanding pathogenesis is just now being realised. Evidence has accumulated that axons are also impaired to some degree, although it is not yet clear whether this represents a primary or secondary effect.
The cause of MS remains an enigma. Although potentially important details of the immune events that occur in individuals with MS have been elucidated, the concept that MS may be an autoimmune disorder remains troubled by failure to unequivocally identify a responsible antigen. The well-documented observation that intercurrent infections are associated with clinical relapses is intriguing, and may support the role of immunopathogenesis. What must be integrated into any concept of etiology is the evidence that an appropriate genetic setting is a requisite for developing MS. Many studies have indicated that the basis for susceptibility depends on multiple genes. To date, efforts to identify a responsible pathogen, virus or otherwise, have failed.
Treatments have been developed, largely by empirical trials of molecules discovered in cognate fields. Adrenal corticosteroids proved to shorten the duration of relapses. This was followed by the discoveries that glatiramer acetate (originally copolymer-1), interferon beta, and most recently mitoxantrone are useful treatments, albeit marginally. Their assessment led to further development and refinement of rigorous clinical trial methodology, now recognized as essential to establish any treatment of MS as evidence-based medicine.
Some of the fundamental unanswered questions that remain include: What cause MS initially? What keeps the process going? What accounts for the enormous individual variation in the progress or lack of progress of the disorder? Why is it more common among women.
Where will the advances come from? The development of truly successful treatments, and perhaps prevention, depends almost entirely on developing an understanding of etiology and pathogenesis. Unraveling the human genome, coupled with increasingly powerful techniques for analyzing candidate genes should yield an understanding of the genetic basis of MS. These studies may lead to clarification of the role of the immune system in disease pathogenesis. Similarly, increasingly powerful approaches such as the use of DNA microarrays and representational difference analysis may uncover an agent that is responsible for starting the MS process. While awaiting advances in disease-altering treatments, increasing understanding of the molecular events that underlie axonal dysfunction in MS will lead to new symptomatic therapies. As research leads to discovery of new agents, increasingly sophisticated imaging will almost certainly reduce the numbers of subjects needed for clinical trials, and provide objective markers of success.
For many individuals who have already sustained impairment, the promise of stem cell research as a route to enhancing remyelination appears extraordinarily promising.
Many readers will interpret both past and possible future research in quite different ways than I have described in this brief account. As the evidence emerges that will solve the puzzles, we will have many stimulating papers to read.
Donald Silberberg
